Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.

摘要

Sirs, With improvements in therapy of inflammatory bowel disease (IBD), much of our focus now turns to how to best predict relapse in those with response. Laharie et al. investigated the role of faecal calprotectin (FC) in predicting relapse of Cro-hn's disease in patients induced with infliximab (IFX) and maintained on immuno-modulator (IMM) monotherapy. In the 77% patients who responded to IFX at week 14 (steroid-free with Crohn's disease activity index (CDAI) <150), 46% had a clinical relapse based on CDAI over the next 38 weeks. In this study, FC at week 14 did not predict who in remission would relapse over the next 38 weeks at either of the cutoff levels generally used; C-reactive protein (CRP) was also not predictive.